The objective of this work was to quantify the contribution of the founder mutations BRCA2 c.156_157insAlu and BRCA1 c.3331_3334del for cancer etiology in unselected hospital-based cohorts of patients diagnosed with these rarer cancers in Portugal. This evidence concerns the gene BRCA1 and cancer.